Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Calidi Biotherapeutics ( (CLDI) ) has provided an update.
Calidi Biotherapeutics has unveiled promising data showcasing its innovative RTNova systemic virotherapy technology, designed to effectively target metastatic lung cancer and other oncology indications. By utilizing a novel strain of vaccinia virus, RTNova overcomes challenges like rapid immune clearance, offering robust potential in treating and possibly transforming tumor environments. This advancement signifies a potential breakthrough in antitumor therapies, with opportunities for collaborative ventures with pharmaceutical partners.
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.
